Skip to main content

Kindly His’ Home Sperm Test Kit

Hormonal health care can be daunting because it touches the most intimate parts of our lives. Kindly wants to make it available to more people, with a combination of at-home diagnostic tests (including semen tests and tests for polycystic ovary syndrome), telehealth consultations and supplements.

The Bangalore-based startup, which has ambitions to expand into global markets, announced today that it has raised a $3.25 million seed round from investors including Y Combinator, Olive Tree, Soma, Goodwater and Gaingels.

Kindly offers two product lines, KindlyHis and KindlyHers. KindlyHers will launch a predictive PCOS test that can help women diagnose and manage PCOS. It also sells routine lab work for PCOS profiles and STD diagnosis. KindlyHis semen tests allow users to take the test at home and then send it to a testing center for diagnosis.

Kindly was founded in 2020 by Nilay Mehrotra, its CEO, and formerly known as Janani.life. Mehrotra told TechCrunch that before joining Y Combinator’s 2022 winter cohort, Kindly was focusing on fertility, specifically building a B2B tool for IVF clinics that would help them select the right embryo.

“But as we begin to better understand the market and our customers, we realized that the problem was indeed much bigger and that we needed to focus on lifestyle disorders,” he said. “We realized that home sperm testing and diagnostics had a much bigger use case than just fertility and we didn’t want to limit ourselves to that.”

Since launching a month ago, Mehrotra said revenue growth has been trending 30% month-over-month, and the company expects to hit $1 million in revenue by the end of the year. year.

Mehrotra says the market opportunity in India for lifestyle disorders, sexual performance and hormonal wellbeing is $8 billion, based on the startup’s findings that 130 million people in India spend around $60 on sexual wellness and performance products.

Going forward, Kindly will also focus on more wellness categories and expand its product portfolio to include eczema, psoriasis and gut health. Its goal is to acquire 130 million users and plans to launch an application in the coming months.